Sunesis Announces Extension of Small Molecule Collaboration with Johnson & Johnson Pharmaceutical Research & Development
SOUTH SAN FRANCISCO, Calif., Jan. 15 /PRNewswire/ -- Sunesis Pharmaceuticals, Inc. announced today that Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and the Company have extended for one year their research collaboration. Initiated in May 2002, the collaboration is focused on the discovery of small molecule enzyme inhibitors for the treatment of major chronic diseases, including inflammatory and autoimmune diseases.
"The continued progress of this program is due to the strong commitment and complementary resources provided by both parties," stated Dan Swisher, CEO of Sunesis. "We are generating compelling results in this collaboration and further validating our fragment-based approach to discover novel therapeutics for important disease targets."
Under the terms of the collaboration agreement, Sunesis receives research funding and will receive additional research and development milestones, as well as royalty payments upon the advancement and commercialization of small molecule enzyme inhibitors based on an exclusive, worldwide license to products resulting from the collaboration. The specific terms of the collaboration are undisclosed.
Sunesis is a research-and-development-based pharmaceutical company that applies fragment-based drug discovery to create superior therapeutics for challenging and important disease targets. Sunesis is building a pipeline of innovative therapeutics addressing major diseases through internal development and selective partnering. For further information, visit www.sunesis.com. |
